DESOWEN desonide 0.5 mg/g lotion bottle Australia - English - Department of Health (Therapeutic Goods Administration)

desowen desonide 0.5 mg/g lotion bottle

galderma australia pty ltd - desonide, quantity: 0.5 mg/g - lotion - excipient ingredients: light liquid paraffin; propylene glycol; sorbitan monostearate; stearyl alcohol; sodium lauryl sulfate; self-emulsifying glyceryl monostearate; cetyl alcohol; methyl hydroxybenzoate; edetate sodium; propyl hydroxybenzoate; sodium hydroxide; citric acid; purified water - desowen lotion 0.05% is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses for adults and children aged 2 years and older.

DESOWEN Desonide 0.5mg/g ointment tube Australia - English - Department of Health (Therapeutic Goods Administration)

desowen desonide 0.5mg/g ointment tube

galderma australia pty ltd - desonide, quantity: 0.5 mg/g - ointment - excipient ingredients: liquid paraffin; polyethylene - desowen ointment 0.05% is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses for adults and children aged 2 years and older.

DESOWEN Desonide 0.5mg/g cream tube Australia - English - Department of Health (Therapeutic Goods Administration)

desowen desonide 0.5mg/g cream tube

galderma australia pty ltd - desonide, quantity: 0.5 mg/g - cream - excipient ingredients: emulsifying wax; propylene glycol; stearic acid; isopropyl palmitate; synthetic beeswax; polysorbate 60; sorbic acid; potassium sorbate; propyl gallate; sodium hydroxide; citric acid; purified water - desowen cream 0.05% is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses for adults and children aged 2 years and older.

ADESAN HCT 32/25 candesartan cilexetil/hydrochlorothiazide 32 mg/25 mg tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

adesan hct 32/25 candesartan cilexetil/hydrochlorothiazide 32 mg/25 mg tablets blister pack

alphapharm pty ltd - candesartan cilexetil, quantity: 32 mg; hydrochlorothiazide, quantity: 25 mg - tablet - excipient ingredients: hyprolose; magnesium stearate; glyceryl monostearate; carmellose calcium; lactose monohydrate; maize starch; iron oxide yellow; iron oxide red - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

ADESAN HCT 32/12.5 candesartan cilexetil/hydrochlorothiazide 32 mg/12.5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

adesan hct 32/12.5 candesartan cilexetil/hydrochlorothiazide 32 mg/12.5 mg tablet blister pack

alphapharm pty ltd - hydrochlorothiazide, quantity: 12.5 mg; candesartan cilexetil, quantity: 32 mg - tablet - excipient ingredients: carmellose calcium; hyprolose; maize starch; glyceryl monostearate; lactose monohydrate; magnesium stearate; iron oxide yellow - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

CANDESAN COMBI 32/25 candesartan cilexetil 32 mg & hydrochlorothiazide 25 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

candesan combi 32/25 candesartan cilexetil 32 mg & hydrochlorothiazide 25 mg tablet blister pack

arrotex pharmaceuticals pty ltd - candesartan cilexetil, quantity: 32 mg; hydrochlorothiazide, quantity: 25 mg - tablet, uncoated - excipient ingredients: carmellose calcium; lactose monohydrate; macrogol 8000; magnesium stearate; hyprolose; maize starch; iron oxide red - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

CANDESAN COMBI 32/12.5 candesartan cilexetil 32 mg & hydrochlorothiazide 12.5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

candesan combi 32/12.5 candesartan cilexetil 32 mg & hydrochlorothiazide 12.5 mg tablet blister pack

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; candesartan cilexetil, quantity: 32 mg - tablet, uncoated - excipient ingredients: hyprolose; iron oxide yellow; lactose monohydrate; magnesium stearate; maize starch; carmellose calcium; macrogol 8000 - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

CANDESAN COMBI 16/12.5 candesartan cilexetil 16 mg & hydrochlorothiazide 12.5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

candesan combi 16/12.5 candesartan cilexetil 16 mg & hydrochlorothiazide 12.5 mg tablet blister pack

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; candesartan cilexetil, quantity: 16 mg - tablet, uncoated - excipient ingredients: carmellose calcium; hyprolose; maize starch; macrogol 8000; magnesium stearate; lactose monohydrate; iron oxide red - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

ADESAN candesartan cilexetil 8 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

adesan candesartan cilexetil 8 mg tablet blister pack

alphapharm pty ltd - candesartan cilexetil, quantity: 8 mg - tablet, uncoated - excipient ingredients: magnesium stearate; carmellose calcium; glyceryl monostearate; hyprolose; iron oxide red; lactose monohydrate; maize starch - treatment of hypertension. treatment of patients with heart failure and impaired left ventricular systolic function, left ventricular ejection fraction less than or equal to 40 percent, as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

ADESAN candesartan cilexetil 4 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

adesan candesartan cilexetil 4 mg tablet blister pack

alphapharm pty ltd - candesartan cilexetil, quantity: 4 mg - tablet, uncoated - excipient ingredients: hyprolose; glyceryl monostearate; magnesium stearate; carmellose calcium; lactose monohydrate; maize starch - treatment of hypertension. treatment of patients with heart failure and impaired left ventricular systolic function, left ventricular ejection fraction less than or equal to 40 percent, as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.